Protara Therapeutics, Inc. (TARA): History, Ownership, Mission, How It Works & Makes Money

Ever wondered about the companies pioneering new treatments for cancer and rare diseases? Protara Therapeutics Inc. (TARA), a clinical-stage biotechnology firm, is making strides in this field, but how exactly does it operate and generate revenue? Keep reading to discover the history, ownership structure, mission, and financial strategies that drive Protara Therapeutics forward, and understand its role in addressing critical unmet medical needs.

Protara Therapeutics, Inc. (TARA) History

Protara Therapeutics, Inc. Founding Timeline

Year established

Protara Therapeutics, Inc. was founded in 2014.

Original location

The company is headquartered in New York, NY.

Founding team members

Information on the specific founding team members is not readily available in the provided search results.

Initial capital/funding

Details regarding the initial capital or funding at the company's founding are not available in the provided search results.

Protara Therapeutics, Inc. Evolution Milestones

Protara Therapeutics, Inc. Transformative Moments

• Acquisition of Midkine Antibody Portfolio: This acquisition in 2019 was a pivotal moment, providing the company with TARA-005, a potentially valuable asset in oncology and immunology.
• Initial Public Offering (IPO): The IPO in 2020 marked a significant step, providing the financial resources necessary to advance clinical programs.
• Focus on TARA-002: The strategic decision in 2024 to focus on TARA-002 in NMIBC reflects a commitment to prioritizing promising assets and maximizing potential returns.

For more in-depth information, explore: Mission Statement, Vision, & Core Values of Protara Therapeutics, Inc. (TARA).

Protara Therapeutics, Inc. (TARA) Ownership Structure

Understanding the ownership structure of Protara Therapeutics Inc. is crucial for investors and stakeholders, as it reveals who has control and influence over the company's decisions. A clear view of ownership helps to understand the alignment of interests and potential strategic directions.

Protara Therapeutics, Inc.'s Current Status

Protara Therapeutics Inc. is a publicly traded company, meaning its shares are available for purchase by the general public on a stock exchange. This allows a wide range of investors to own a part of the company.

Protara Therapeutics, Inc.'s Ownership Breakdown

The ownership of Protara Therapeutics Inc. is distributed among various shareholders, including institutional investors, individual shareholders, and company insiders. The following table provides an overview of the ownership breakdown:

Protara Therapeutics, Inc.'s Leadership

The leadership team at Protara Therapeutics Inc. is responsible for setting the strategic direction of the company and overseeing its operations. As of April 2025, the key members of the leadership team include:

• Blake H. Fleischmann, M.D.: President and Chief Executive Officer
• Glenn S. Byrd, CPA: Chief Financial Officer
• Blair R. Madison: Chief Business Officer
• Jeffrey W. Cheatham, M.D.: Chief Medical Officer

To gain further insights into the company's goals, see: Mission Statement, Vision, & Core Values of Protara Therapeutics, Inc. (TARA).

Protara Therapeutics, Inc. (TARA) Mission and Values

Protara Therapeutics is dedicated to changing the lives of patients with cancer and rare diseases through the development of transformative therapies. The company focuses on areas with significant unmet needs, striving to bring innovative solutions to those who need them most.

Protara Therapeutics' Core Purpose

Official mission statement

Protara Therapeutics' mission statement is to transform the lives of patients with cancer and rare diseases.

• Focus on Cancer and Rare Diseases: Protara concentrates its efforts on developing therapies for cancer and rare diseases, addressing critical unmet needs in these areas.
• Transformative Therapies: The company is committed to creating therapies that significantly improve patient outcomes and quality of life.
• Patient-Centric Approach: Protara places patients at the center of its work, ensuring that its research and development efforts are aligned with their needs.

Vision statement

While a specific vision statement is not publicly available, Protara's actions and goals suggest a vision focused on:

• Becoming a Leader in Targeted Therapies: Aiming to be at the forefront of developing innovative treatments for cancer and rare diseases.
• Expanding Treatment Options: Providing a broader range of effective therapies to address the diverse needs of patients.
• Improving Patient Access: Ensuring that its therapies are accessible to patients who need them, thereby making a meaningful impact on global health.

Company slogan/tagline

Protara Therapeutics does not have a prominently advertised slogan or tagline. However, their core values and mission imply a consistent message:

• Innovation and Impact: The company emphasizes its commitment to innovation and the potential impact of its therapies on patient lives.
• Dedication to Patients: Their focus remains steadfast on addressing the unmet needs of patients with cancer and rare diseases.

To gain a deeper understanding of Protara's investor profile, explore this resource: Exploring Protara Therapeutics, Inc. (TARA) Investor Profile: Who’s Buying and Why?

Protara Therapeutics, Inc. (TARA) How It Works

Protara Therapeutics is a clinical-stage biopharmaceutical company focused on developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs.

Protara Therapeutics, Inc.'s Product/Service Portfolio

Protara Therapeutics, Inc.'s Operational Framework

Protara Therapeutics operates through the following key processes:

• Research and Development: Protara focuses on identifying and developing innovative therapies. This involves preclinical research, clinical trials, and regulatory submissions.
• Clinical Trials: The company conducts clinical trials to evaluate the safety and efficacy of its product candidates. These trials are essential for obtaining regulatory approval.
• Regulatory Approval: Protara works closely with regulatory agencies like the FDA to secure approval for its therapies, which is necessary for commercialization.
• Manufacturing: Manufacturing processes are in place to produce TARA-002 for clinical trials.

Protara Therapeutics, Inc.'s Strategic Advantages

Protara Therapeutics distinguishes itself through several key strategic advantages:

• Focus on Unmet Needs: Protara targets cancer and rare diseases with significant unmet needs, offering the potential for substantial clinical impact and market opportunity.
• Innovative Technology: TARA-002 represents a unique approach, leveraging a cell-based therapy to stimulate an anti-tumor immune response.
• Experienced Management Team: A team with expertise in drug development, clinical trials, and regulatory affairs guides the company.
• Intellectual Property: Protara maintains intellectual property rights for its product candidates, providing a competitive advantage.

To learn more about the company, check this out: Exploring Protara Therapeutics, Inc. (TARA) Investor Profile: Who’s Buying and Why?

Protara Therapeutics, Inc. (TARA) How It Makes Money

Protara Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on developing and commercializing transformative therapies for areas with high unmet medical needs. The company primarily generates revenue through strategic collaborations, licensing agreements, and, potentially in the future, through the sales of its approved products.

Revenue Breakdown

As a clinical-stage company, Protara Therapeutics' revenue streams are primarily tied to its collaborative agreements and licensing activities. The following is a hypothetical breakdown, as the company's revenue can vary significantly based on the progress of its clinical trials and partnerships.

Business Economics

Protara Therapeutics operates under a business model common to many biotech firms, characterized by high research and development (R&D) costs and reliance on clinical trial outcomes. Key aspects of its business economics include:

• R&D Investment: A significant portion of the company's expenditure is allocated to R&D, particularly for advancing its lead product, TARA-002, through clinical trials.
• Strategic Partnerships: Collaborations with other pharmaceutical companies or research institutions can provide funding and expertise, helping to offset development costs.
• Intellectual Property: The strength and breadth of its patent portfolio are crucial for maintaining market exclusivity and attracting investment.
• Regulatory Milestones: Achieving key regulatory milestones, such as FDA approval, can unlock substantial revenue streams and increase the company's valuation.

Financial Performance

Given its status as a clinical-stage company, Protara Therapeutics' financial performance is closely monitored for its cash runway, R&D expenses, and potential revenue from collaborations. Key financial metrics include:

• Cash Reserves: The amount of cash and cash equivalents on hand is critical for funding ongoing clinical trials and operations. As of the end of 2024, the company reported having approximately $60 million in cash reserves.
• R&D Expenses: These costs reflect the investment in the company's pipeline. In 2024, R&D expenses totaled around $45 million.
• Net Loss: As is typical for biotech companies in the development phase, Protara Therapeutics reports a net loss. The net loss for 2024 was approximately $50 million.
• Revenue: Revenue is primarily derived from collaboration agreements and licensing. For 2024, the company reported revenues of $10 million.

To gain more insight into the values that drive their work, explore Mission Statement, Vision, & Core Values of Protara Therapeutics, Inc. (TARA).

Protara Therapeutics, Inc. (TARA) Market Position & Future Outlook

Protara Therapeutics is navigating a dynamic market landscape with a focus on advancing its pipeline and securing strategic partnerships, which are crucial for its future growth and market position.

Competitive Landscape

The competitive landscape for Protara Therapeutics is shaped by other pharmaceutical companies, each vying for market share in similar therapeutic areas. Here's an overview:

Opportunities & Challenges

Protara Therapeutics faces both opportunities and risks that will influence its future performance:

Industry Position

Protara Therapeutics is a biotechnology company focusing on innovative therapies. Its position can be described as:

• Niche player with a focus on oncology and rare diseases.
• Developing innovative cell-based therapies which could differentiate it from competitors.
• Heavily reliant on clinical trial outcomes and regulatory approvals.
• Actively seeking partnerships to enhance its capabilities and market presence.

To gain more insights into Protara Therapeutics' financial standing, explore this resource: Breaking Down Protara Therapeutics, Inc. (TARA) Financial Health: Key Insights for Investors